6533b7d8fe1ef96bd126a2ea

RESEARCH PRODUCT

Targeting Oxidative Stress as a Therapeutic Approach for Idiopathic Pulmonary Fibrosis

Cristina EstornutJavier MilaraJavier MilaraJavier MilaraMaría Amparo BayarriNada BelhadjJulio CortijoJulio CortijoJulio CortijoJulio Cortijo

subject

PharmacologyIPF—idiopathic pulmonary fibrosisantioxidant therapyfibrosisoxidative stressPharmacology (medical)Therapeutics. PharmacologyRM1-950Reviewrespiratory systemROS—reactive oxygen speciesrespiratory tract diseases

description

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis within the alveolar wall that are not due to infection or cancer. Oxidative stress has been proposed as a key molecular process in pulmonary fibrosis development and different components of the redox system are altered in the cellular actors participating in lung fibrosis. To this respect, several activators of the antioxidant machinery and inhibitors of the oxidant species and pathways have been assayed in preclinicalin vitroandin vivomodels and in different clinical trials. This review discusses the role of oxidative stress in the development and progression of IPF and its underlying mechanisms as well as the evidence of oxidative stress in human IPF. Finally, we analyze the mechanism of action, the efficacy and the current status of different drugs developed to inhibit the oxidative stress as anti-fibrotic therapy in IPF.

10.3389/fphar.2021.794997http://europepmc.org/articles/PMC8815729